GRCE: Grace Therapeutics Inc PEG Multiple
Grace Therapeutics, Inc. (GRCE) attracts top biochemists through an ethical culture and stock options, while outsourcing production to third-party contractors to maintain flexibility. The P/E growth potential ratio reflects the outcome of this strategy, and this metric stands at 0.00. High demand for advanced injections for rare nervous system pathologies promises the company a significant expansion of its client base.
Grace Therapeutics, Inc. (GRCE) - metric breakdowns and financial figures
- share price and consensus valuation forecast:
- market capitalization information:
- balance sheet equity data:
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Grace Therapeutics, Inc.|GRCE - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio gracetx.com|GRCE - Company Aggregate Debts|Debt to Net Assets Ratio Grace Tx|GRCE - Company Long-Term Debts|Short-Term Debt Grace Therapeutics|Intermediate Coverage Ratio gracetx.com
- business earnings and investment ratios data:
GRCE - Net Profit|Projected Future Earnings Grace Therapeutics, Inc.|GRCE - Price to Earnings Ratio|Price to Expected Earnings Ratio gracetx.com|GRCE - PEG Multiple|Company Value to EBITDA Grace Tx|GRCE - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Grace Therapeutics|GRCE - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months gracetx.com|GRCE - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Grace Therapeutics, Inc.
- issuer revenue and sales details:
General company analysis:Grace Therapeutics Inc, GRCE
Grace Therapeutics, Inc. (GRCE) focuses on clinical trials for neurological pathology drugs and currently has no sources of commercial revenue. Under these conditions, the adjusted PEG ratio compares market valuation with earnings growth dynamics. This metric determines whether the multiple is fair relative to the pace of business expansion. A value below one signals that the asset is undervalued. Analyzing this curve allows for the identification of potential for a sharp increase in the company's value.
Competing companies
BIIB (Biogen Inc) - Growth-Adjusted Payback Ratio|PEG Multiple NBIX (Neurocrine Biosciences Inc)|PEG Multiple Regencell Corp RGC|Axsome Therapeutics - PEG Multiple|acadia-pharm.com (ACAD) - Price/Earnings to Growth Multiple|XENE: PEG Multiple|Price to Earnings Adjusted for Growth Rate Viking Therapeutics Inc (VKTX)|Price/Earnings to Growth Multiple SUPN|CPRX: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Multiple DNLI (Denali Therapeutics)|Company Value to Earnings Growth Ratio HRMY|PEG Multiple BHVN (Biohaven)|Growth-Adjusted Payback Ratio AMLX|Trevi Pharma - PEG Multiple|Price to Earnings Adjusted for Growth Rate Praxis Corp|Anavex Life Sciences (AVXL) - Price/Earnings to Growth Ratio|ceribell.com - Growth-Adjusted Payback Ratio|PRTA (Prothena Corporation plc) - PEG Multiple|PEG Multiple Alector Therapeutics|Price/Earnings to Growth Ratio Annexon Inc. (ANNX)|OMER: Market Cap to Earnings and Growth Ratio|PEG Multiple NGNE (Neurogene Inc.)|acimmune.com (ACIU) - Price to Earnings Adjusted for Growth Rate|VYGR: Price/Earnings to Growth Multiple|NMRA - PEG Multiple|SCLX (Scilex Holding Co.) - Price/Earnings to Growth Multiple|TVGN: Company Value to Earnings Growth Ratio|ACOG (Alpha Cognition Inc) - PEG Multiple|cogrx.com (CGTX) - Growth-Adjusted Market Cap to Net Income|PEG Multiple IKT|Price/Earnings to Growth Multiple Cassava Sciences Inc SAVA|Price/Earnings to Growth Ratio Assertio ASRT|Growth-Adjusted Market Cap to Net Income Coya Therapeutics Inc (COYA)|VTGN: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio OVID (Ovid Therapeutics Inc.)|ABOS: PEG Multiple|CRVO - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Alterity Therapeutics Ltd.|Growth-Adjusted P/E Ratio CLNN (Clene Nanomedicine)|PEG Multiple PEPG|Price/Earnings to Growth Multiple jupiterneurosciences.com JUNS|Relmada Therapeutics, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income Annovis Bio Inc (ANVS)|Firefly Neuroscience Inc - PEG Multiple|Price to Net Income Growth Ratio Klotho Neurosciences Inc (KLTO)|neurosense-tx.com (NRSN) - Price/Earnings to Growth Ratio|revivapharma.com - Growth-Adjusted Payback Ratio|MTVA (MetaVia Inc.) - PEG Multiple|Price/Earnings to Growth Multiple NeurAxis Inc. (NRXS)|PEG Multiple HSDT|PASG - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Neuphoria Therapeutics NEUP|NERV: Growth-Adjusted P/E Ratio|Athira Pharma - PEG Multiple|Price to Earnings Adjusted for Growth Rate Addex Therapeutics Ltd.|ALZN (alzamend.com) - Price/Earnings to Growth Multiple|Cyclerion Therapeutics, Inc. (CYCN) - PEG Multiple|Price/Earnings to Growth Ratio Protagenic Therapeutics Inc.|KTTA: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Cortigent, Inc. (CRGT)|ATXI - Price to Earnings Adjusted for Growth Rate|PEG Multiple BCLI (Brainstorm Cell Therapeutics, Inc.)|Price to Net Income Growth Ratio Cara Therapeutics Inc|CHRO - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio ELYM (Eliem Therapeutics)|ITCI: PEG Multiple|Longboard Pharmaceuticals Inc (LBPH) - PEG Multiple|MRNS (Marinus) - PEG Multiple|Price/Earnings to Growth Multiple NKGen Biotech Corp (NKGN)|PEG Multiple NRBO|SAGE - Price to Earnings Adjusted for Growth Rate|Synaptogenix - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio TRVN|VIGL: Price/Earnings to Growth Multiple|Anew Medical Inc. - Company Value to Earnings Growth Ratio|CERE: PEG Multiple
